PepEvolutionNAD+
A central metabolic cofactor sold as an IV/injectable longevity therapy — broadly benign, but the direct-injection evidence is thin.
Verdict — C · Emerging / Mixed
A genuinely important molecule with a benign safety profile, but the popular injectable/IV longevity use is weakly evidenced relative to oral precursors, and the infusion experience is uncomfortable. A C — used widely in the wild, but the direct-injection evidence isn't there yet.
Overview
NAD+ (nicotinamide adenine dinucleotide) is a redox cofactor essential to cellular energy metabolism and DNA repair, and is not a peptide. It is marketed heavily as an intravenous or subcutaneous longevity and "cellular energy" therapy. The stronger human evidence sits with oral NAD+ precursors (nicotinamide riboside, NMN) rather than with direct NAD+ injection/infusion, which has a much thinner clinical base. Safety is generally favourable — the main complaints are infusion-related flushing, nausea and chest tightness during rapid administration.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.